MedImmune Inc

Activities: Manufacturing Research & Development Pharmaceutical

Trending Articles

  1. Thermo Fisher Scientific officially opens US oral solid dose testing and R&D facility The company's further expansion in the Bend, Oregon area will assist its pharmaceutical clients in the early development of oral solid dosage (OSD) forms
  2. Amgen invests $1bn into new US drug manufacturing facility The site will be the CDMO's second drug substance manufacturing facility in North Carolina, and will boost its presence in the US pharmaceutical market
  3. Reckitt expands US OTC manufacturing footprint with North Carolina facility The site in Wilson will be responsible for producing Mucinex® branded tablets and liquids, which are designed as over the counter (OTC) medicines for cold and flu symptoms
  4. Precision psychiatry in action: How IMed Consultancy helped HMNC Brain Health’s Cortibon programme AI-driven approach promises a new class of depression treatment
  5. Pharma Packaging and Labelling Forum 27–28 May 2025 | Conference | Basel, Switzerland

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Media

Merck is set to lead pharmaceutical licensing deals in 2018

GlobalData, a specialist data and analytics company, expects that 2018 is likely to be Merck’s year in terms of research and development collaboration
Research & Development

MedImmune and Abpro enter into a collaborative agreement for a novel bispecific antibody

Agreement to result in new spin out company, AbMed, as subsidiary of Abpro
Research & Development

AstraZeneca launches integrated genomics approach to transform drug discovery and development

The initiative includes new collaborations with Human Longevity, the Wellcome Trust Sanger Institute and The Institute for Molecular Medicine
Research & Development

AstraZeneca and Moderna Therapeutics link up to develop immuno-oncology mRNA therapeutics

Extension to an mRNA agreement for cardiovascular, metabolic and renal diseases set up in 2013
Manufacturing

Wacker Biotech grants MedImmune licence to use Esetec technology to manufacture antibody fragment

To help improve productivity and simplify the purification process
Research & Development

AstraZeneca signs third cancer deal in seven days

MedImmune enters into cancer vaccine collaboration and license agreement with Inovio Pharmaceuticals
Research & Development

Medimmune partners with the University of Sheffield to innovate cell factory technology

Partnership will create tools that could increase the yield and predictability of engineered proteins such as bispecific antibodies to treat a range of diseases
Subscribe now